HELİCOBACTER PYLORİ ERADİKASYONU TAKİBİNDE NÖTROFİL/LENFOSİT ORANININ ÖNEMİ

Year 2019, Volume: 52 Issue: 1, 38 - 42, 14.03.2019

Murat Ferhat Ferhatoğlu , Kazım Şenol Abdulcabbar Kartal Taner Kıvılcım Ali İlker Filiz

Abstract

GİRİŞ
ve AMAÇ: Üst sindirim sistemine ait birçok hastalığın
etyopatogenezinde rol oynayan helicobacter pylori insanlarda en sık görülen
kronik bakteriyel enfeksiyondur. Prevalansı sosyokültürel ve coğrafi bölgelere
göre değişkenlik gösteren bu patojen dünya nüfusunun %30-%50'sini
etkilemektedir. Yıllar içerisine artan antibiyotik kullanımı ve sanitasyon
koşullarındaki değişiklikler nedeniyle bu yaygın enfeksiyonun davranış şekli de
değişiklik göstermiştir. Bu çalışmamızda birçok merkezde kolaylıkla yapılabilen
bir tetkik olan tam kan sayımında bulunan ve enfeksiyon belirteci olabilecek
parametreler ile helicobacter pylori enfeksiyonu arasındaki ilişkiyi inceledik.

YÖNTEM
ve GEREÇLER: Bu çalışmamızda Ocak
2016- Aralık 2016 üst gastrointestinal sistem endoskopisi yapılan 2939
hastanın tam kan sayımı ve patoloji verileri retrospektif olarak inceledik.

BULGULAR: Helicobacter
pylori varlığına göre nötrofil/lenfosit oranı arasında istatistiksel olarak anlamlı
farklılık saptanmış ve helicobacter pylori (+) olguların NLR değerleri helicobacter
pylori (-) olgulara göre yüksek bulunmuştur.

TARTIŞMA ve SONUÇ: Nötrofil/lenfosit
oranının helicobacter pylori eradikasyonu tedavi sürecini takip etmek için
yararlı olabileceğini düşünmekteyiz.

Keywords

Helicobacter pylori, nötrofil/lenfosit, gastrit, eradikasyon

References

• Cave DR. Transmission and epidemiology of Helicobacter pylori. Am J Med. 1996; 100: 12–7.
• Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995; 9: 33– 9.
• Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2014; 19: 1-5.
• Thung I, Aramin H, Vavinskaya V, et al. The global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016; 43: 514-33.
• Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol. 2010; 25: 479-86.
• O’Connor A, O’Morain C. Helicobacter pylori infection in Europe: current perspectives. Expert Rev Gastroenterol Hepatol. 2013; 7: 541- 8.
• Inoue M. Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer. 2017; 20: 3-7.
• Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018; 47: 868–76.
• den Hollander WJ, Holster IL, den Hoed CM, et al. Ethnicity is a strong predictor for Helicobacter pylori infection in young women in a multi-ethnic European city. J Gastroenterol Hepatol 2013; 28: 1705–11.
• Alvarado-Esquivel C. Seroepidemiology of Helicobacter pylori infection in pregnant women in rural durango. Mexico Int J Bio- med Sci 2013; 9: 224–9.
• Adlekha S, Chadha T, Krishnan P, Sumangala B. Prevalence of Helicobacter pylori infection among patients undergoing upper gastrointestinal endoscopy in a medical college hospital in ker- ala, India. Ann Med Health Sci Res 2013; 3: 559–63.
• Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemey- eva K, Paloheimo L, Syrj€anen K. Prevalence of H. pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers. Anticancer Res 2013; 33: 4595–602.
• Dorji D, Dendup T, Malaty HM, Wangchuk K, Yangzom D, Richter JM. Epidemiology of Helicobacter pylori in Bhutan: the role of environment and Geographic location. Helicobacter 2014; 19: 69–73.
• Hanafi MI, Mohamed AM. Helicobacter pylori infection: seropre- valence and predictors among healthy individuals in Al Madi- nah, Saudi Arabia. J Egypt Public Health Assoc 2013; 88: 40–5.
• Mana F, Vandebosch S, Miendje Deyi V, Haentjens P, Urbain D. Prevalence of and risk factors for H. pylori infection in healthy children and young adults in Belgium anno 2010/ 2011. Acta Gastroenterol Belg 2013; 76: 381–5.
• Benajah DA, Lahbabi M, Alaoui S, El Rhazi K, El Abkari M, Nejjari C, Amarti A, Bennani B, Mahmoud M, Ibrahimi SA. Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco). Clin Res Hepatol Gastroenterol 2013; 37: 519–26.
• Mathewos B, Moges B, Dagnew M. Seroprevalence and trend of Helicobacter pylori infection in Gondar University Hospital among dyspeptic patients, Gondar, North West Ethiopia. BMC Res Notes 2013; 6: 346.
• Ghasemi-Kebria F, Ghaemi E, Azadfar S, Roshandel G. Epide- miology of Helicobacter pylori infection among Iranian children. Arab J Gastroenterol 2013; 14: 169–72.
• Sethi A, Chaudhuri M, Kelly L, Hopman W. Prevalence of Heli- cobacter pylori in a First Nations population in northwestern Ontario. Can Fam Physician 2013; 59: 182–7.
• Zhu Y, Zhou X, Wu J, Su J, Zhang G. Risk factors and preva- lence of Helicobacter pylori infection in persistent high incidence area of gastric carcinoma in Yangzhong city. Gastroenterol Res Pract 2014; 2014: 481365.
• Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374: 1449–61.
• Malfertheiner P, Mégraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV Florence Consensus Report. Gut 2012; 61: 646–64.
• Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64:1353–67.
• Uemura N, Okamoto S, Yamamoto S, et al. H. pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–9.
• Miehlke S, Hackelsberger A, Meining A, et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 1998; 78: 263–6.
• Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 321: 1273-5.
• Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfill Koch’s postulates for pyloric Campylobacter. Med J Aust 1985; 142: 436-9.
• Correa P. The gastric precancerous process. Cancer Surv 1983;2 : 437-50.
• Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975;306:58-60.
• Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014; 348: 3174
• Wong BC, Lam SK, Womg MW, et al. Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China A Randomized Controlled Trial. JAMA. 2004; 291: 187-94.
• Farah R, Khamisy-Farah R. Association of Neutrophil to Lymphocyte Ratio With Presence and Severity of Gastritis Due to Helicobacter pylori Infection. Journal of Clinical Laboratory Analysis 2014; 28: 219–23.
• Umit H, Umit EG. Helicobacter pylori and mean platelet volume: a relation way before ımmune thrombocytopenia? Eur Rev Med Pharmacol Sci. 2015; 19: 2818-23.